Nakamura T, Ide H, Eguchi R, Hayashi K, Hanyu F, Nagasako K, Yukawa M, Asaka K, Fujimori T, Maeda S
Department of Surgery, Tokyo Women's Medical College, Japan.
Surg Today. 1995;25(7):591-7. doi: 10.1007/BF00311431.
We examined the p53 protein and human papilloma virus (HPV) by immunohistochemistry and DNA ploidy by cytofluorometry in paraffin-embedded esophageal carcinoma tissue specimens. Sixty-one patients with superficial esophageal carcinoma were operated on between 1983 and 1991 without any prior treatment. Immunostaining of the anti-p53 protein antibody (CM1) was positive in 32 carcinomas (52%). Patients with p53-positive tumors had a poorer outcome than those with p53-negative tumors (P < 0.05). In addition, patients with p53-positive tumors did not have any characteristic site of relapse. Only 5 of the 61 patients (8.2%) had HPV-positive tumors. One of these 5 carcinomas expressed both p53 protein and HPV. Three patients with HPV-positive tumors which had invaded the submucosal layer died of relapse. A determination of DNA ploidy revealed 30 patients with aneuploid tumors, 13 with polyploid tumors and 18 with diploid tumors. The outcome of the patients with aneuploid tumors was worse than that of the patients with diploid tumor (P < 0.05). p53 protein expression was not associated with DNA ploidy; however, the 16 patients who had both p53-positive and aneuploid tumors had a worse prognosis than patients with p53-negative and aneuploid tumors (P < 0.01). These findings suggest that p53 protein expression in conjunction with DNA ploidy may be a useful indicator in evaluating the prognosis of patients with superficial esophageal carcinoma.
我们通过免疫组织化学检测了石蜡包埋的食管癌组织标本中的p53蛋白和人乳头瘤病毒（HPV），并通过细胞荧光测定法检测了DNA倍体。1983年至1991年间，61例浅表性食管癌患者在未接受任何前期治疗的情况下接受了手术。抗p53蛋白抗体（CM1）免疫染色在32例癌组织中呈阳性（52%）。p53阳性肿瘤患者的预后比p53阴性肿瘤患者差（P<0.05）。此外，p53阳性肿瘤患者没有任何特征性的复发部位。61例患者中只有5例（8.2%）肿瘤HPV阳性。这5例癌组织中有1例同时表达p53蛋白和HPV。3例HPV阳性且已侵犯黏膜下层的肿瘤患者死于复发。DNA倍体测定显示，30例患者为非整倍体肿瘤，13例为多倍体肿瘤，18例为二倍体肿瘤。非整倍体肿瘤患者的预后比二倍体肿瘤患者差（P<0.05）。p53蛋白表达与DNA倍体无关；然而，16例p53阳性且为非整倍体肿瘤的患者比p53阴性且为非整倍体肿瘤的患者预后更差（P<0.01）。这些发现表明，p53蛋白表达结合DNA倍体可能是评估浅表性食管癌患者预后的一个有用指标。
